RTP Mobile Logo
Meet The Professors: Hodgkin Lymphoma Edition, 2018 (Video Program)
Released July 2018

A case-based roundtable discussion on the management of Hodgkin lymphoma. Featuring faculty members Drs John Kuruvilla and Craig H Moskowitz and community oncologists Drs Justin P Favaro, Zanetta Lamar and Neeraj Mahajan. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin lymphoma (HL).

    In contrast to the more prevalent non-Hodgkin lymphomas, HL is a rare cancer that is relatively chemosensitive and often curable when treated appropriately. However, a proportion of affected patients are either diagnosed at a far advanced stage of disease or harbor unfavorable risk factors that confer a suboptimal response to treatment and/or a high probability of early relapse. Historically the therapeutic challenge posed by this HL population was significant because no new systemic agent had been approved in this setting for more than 3 decades. The introduction of brentuximab vedotin and the anti-PD-1 antibodies nivolumab and pembrolizumab has not only improved outcomes but also added tremendous complexity to current treatment decision-making. Extensive published and ongoing research attempting to better define and expand the role of these and other agents leveraging diverse mechanisms of action further add to the realm of educational priorities related to this challenging disease.

    In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with HL.


    • Appreciate the recent FDA approval of brentuximab vedotin in combination with chemotherapy as first-line therapy for Stage III or IV classical HL (cHL), and discern how this regimen can be appropriately and safely integrated into routine clinical practice.
    • Review available and emerging research information outlining the benefits and risks associated with brentuximab vedotin alone or in combination with chemotherapy for patients at first relapse, and use this information to discern for whom this approach may be appropriate prior to referral for autologous stem cell transplant.
    • Develop a long-term care plan for individuals with relapsed/refractory HL, considering exposure to prior systemic therapy, eligibility for transplant, symptoms, performance status and personal goals for treatment.
    • Compare and contrast the efficacy and safety of approved immunotherapeutic approaches for the treatment of HL to determine the current utility of each in clinical practice.
    • Communicate with patients and their caregivers the incidence and manifestation of side effects and toxicities associated with common cytotoxic, biologic and immunotherapeutic strategies for the management of advanced cHL.
    • Recall the design of ongoing clinical trials evaluating approved therapies and novel investigational agents for the treatment of HL, and counsel appropriately selected patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    John Kuruvilla, MD
    Hematologist, Princess Margaret Cancer Centre
    Associate Professor of Medicine
    University of Toronto
    Toronto, Ontario

    Advisory Committee: Merck; Consulting Agreements: Bristol-Myers Squibb Company, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Merck, Roche Laboratories Inc, Seattle Genetics; Other: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Merck, Roche Laboratories Inc, Seattle Genetics.

    Craig H Moskowitz, MD
    Physician in Chief
    Oncology Service Line
    Sylvester Comprehensive Cancer Center
    Department of Medicine
    Miami, Florida

    Advisory Committee: Bristol-Myers Squibb Company, Merck, Seattle Genetics, Takeda Oncology; Consulting Agreements: Merck, Seattle Genetics, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Seattle Genetics Inc, Takeda Oncology.

    COMMUNITY ONCOLOGISTS — The following community oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Justin P Favaro, MD, PhD
    Oncology Specialists of Charlotte PA
    Charlotte, North Carolina

    Advisory Committee: Amgen Inc; Contracted Research: Novartis, Pfizer Inc.

    Zanetta Lamar, MD
    Assistant Professor, Hematology and Oncology
    Maya Angelou Center for Health Equity
    Redox Biology and Medicine Center
    Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina

    Advisory Committee: Seattle Genetics.

    Neeraj Mahajan, MD
    Hematology and Oncology
    Assistant Clinical Professor, Medicine
    CWRU School of Medicine
    UH Parma Medical Center
    UH Seidman Cancer Center
    Parma, Ohio

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2018
    Expiration date: July 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):